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ABSTRACT
Introduction: Influenza vaccination is administered
annually as a preventive measure against influenza
infection and influenza-related complications in high-
risk individuals, such as those with asthma. However,
the effectiveness of influenza vaccination in people with
asthma against influenza-related complications is still
not well established.
Methods and analysis: We will search the following
databases: MEDLINE (Ovid), EMBASE (Ovid),
Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Cochrane Central Register of
Controlled Trials (CENTRAL), Scopus, Cochrane
Database of Systematic Reviews (CDSR), Web of
Science Core Collection, Science direct, WHO Library
Information System (WHOLIS), Global Health Library
and Chinese databases (CNKI, Wanfang and
ChongQing VIP) from Jan 1970 to Jan 2016 for
observational and experimental studies on effectiveness
of influenza vaccine in people with asthma. The
identification of studies will be complemented with the
searching of the reference lists and citations, and
contacting influenza vaccine manufacturers to identify
unpublished or ongoing studies. Two reviewers will
extract data and appraise the quality of each study
independently. Separate meta-analyses will be
undertaken for observational and experimental evidence
using fixed-effect or random-effects models, as
appropriate.
Ethics and dissemination: Formal ethical approval
is not required, as primary data will not be collected.
The review will be disseminated in peer-reviewed
publications and conference presentations.
INTRODUCTION
Inﬂuenza is an acute respiratory illness
caused by infection with the inﬂuenza virus.
Inﬂuenza can cause respiratory tract infec-
tions and results in complications, which can
result in substantial morbidity and in some
cases death.1 2
Worldwide, inﬂuenza causes an estimated
ﬁve million cases of severe illness and half a
million deaths each year. In the USA, for
example, the overall cost to health services is
estimated at US$87 billion per annum.3 4
The burden of inﬂuenza is particularly high
in individuals with chronic medical condi-
tions. Pneumonia and inﬂuenza-related mor-
tality rates range from less than 10/100 000
in healthy adults to over 600/100 000 in
adults with chronic illness.5 In the USA,
during the inﬂuenza seasons 2004–2012,
among 794 ﬂu-associated deaths in children
with or without high-risk medical conditions,
127 (16%) had asthma.6 It is estimated that
8% of asthma exacerbations are caused by
inﬂuenza.7 Groups at increased risk of severe
inﬂuenza include those with asthma, other
chronic diseases, pregnant women, morbid
obesity, individuals over the age of 65 years,
children aged 6 months to 4 years, residents
of nursing homes or chronic care facilities,
and their carers.5 8 9
The Global Initiative for Asthma deﬁnition
for asthma is described as the history of
respiratory symptoms, such as wheeze, short-
ness of breath, chest tightness and cough
that vary over time and in intensity, together
Strengths and limitations of this study
▪ Systematic review of high-quality studies, such
as randomised controlled trials.
▪ The selection of studies, data extraction, and the
quality assessment will be conducted by two
independent authors.
▪ The protocol has been created according to pub-
lished PRISMA-P guidelines.
▪ We do not have any language limitations.
▪ The inclusion of non-randomised studies may
produce evidence of possible bias. Sensitivity
analysis is planned to be conducted to reduce
the risk of poor evidence, by excluding studies at
high risk of bias.
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with variable expiratory airﬂow limitation.10 The inﬂu-
enza virus is a trigger that causes inﬂammation in the
airways of people with asthma resulting in severe compli-
cations, such as exacerbation of asthma, hospitalisation,
or even death. Thus, people with asthma are at risk of
developing inﬂuenza-related complications due to their
sensitive airway system.6 11
Annual immunisation with inﬂuenza vaccine of
people with asthma, is the current preventive measure
against seasonal inﬂuenza and an inﬂuenza-triggered
asthma attack,12 which is recommended by WHO and
many national immunisation technical advisory
groups.9 13–16 According to the UK guidelines, people
with asthma who require continuous or repeated use of
inhaled or systemic steroids, or with previous exacerba-
tions requiring hospital admission, are considered as
having severe asthma, and free inﬂuenza vaccination is
offered.9 However, this varies by country. In addition,
immunoresponse to the inﬂuenza vaccine may be
adversely affected in people with asthma on high-dose
inhaled corticosteroid therapy. However, further evi-
dence is needed regarding the impact of corticosteroids
on immunity induced by the inﬂuenza vaccine.17
Inﬂuenza vaccines currently available worldwide
include: (1) whole virion-inactivated vaccines; (2)
subunit-inactivated vaccines which contain only surface
antigens (H and N); (3) split virion-inactivated vaccines
which contain surface and internal antigens; and (4)
live-attenuated, cold-adapted vaccines in which the live
virus can only multiply in the cooler nasal passages.18
Vaccination is believed to induce a variable degree of
protection (ranging from 0 to 80%) against inﬂuenza
and its complications. The high mutation of the inﬂu-
enza virus and the emergence of new strains, the lack of
carryover protection by previous infection or vaccin-
ation, are some reasons why annual repetition is
required.10 19 20 Additionally, a good antigenic match
between the circulating inﬂuenza virus and the strains
included in the vaccine is required for optimal protec-
tion.21 Thus, regular monitoring of the effectiveness of
inﬂuenza vaccination is needed.
Experimental studies and, in particular, randomised
controlled trials (RCT) are considered the best evidence
for evaluating inﬂuenza vaccines. However, there are
feasibility issues raised when conducting clinical trials
for vaccine efﬁcacy evaluation. These include the costs
involved in the conduct of RCTs. For example, the
average coverage cost per patient enrolment in clinical
trials in the UK was £9900 in 2007.22 Additionally, each
inﬂuenza season should be monitored as the virulence
circulating inﬂuenza virus types are highly variable and
unpredictable. Ethical issues may also be raised when
vaccine effectiveness is assessed in placebo-controlled
trials, as the inﬂuenza vaccine is a recommended
product particularly in clinically high-risk individuals,
such as those with asthma, for the prevention of
inﬂuenza-related complications.23–26 Most RCTs have,
therefore, been conducted in healthy populations, and
only a few in people with asthma or other medical con-
ditions.27–30 Therefore, it is necessary to include observa-
tional studies (despite their poorer quality, compared to
RCTs) as a source of evidence for the evaluation of
inﬂuenza vaccines among high-risk groups.23–25
Additionally, the test-negative (TND) (observational
case–control study) design is considered to be a good
measure of vaccine effectiveness. This is due to the use
of the highly speciﬁc laboratory real-time polymerase
chain reaction (RT-PCR) testing to conﬁrm (or refute)
inﬂuenza among a population exposed or not exposed
to inﬂuenza vaccine.31 32 Although these TND studies
only assess whether the vaccine is an effective interven-
tion against laboratory-conﬁrmed inﬂuenza, this assess-
ment of vaccine effectiveness is an important public
health priority, particularly for at-risk people of
inﬂuenza-related complications.6 33
A systematic review carried out by Cates et al in 2013,
evaluated the effectiveness of inﬂuenza vaccination in
people with asthma. The primary outcome for the Cates
et al review was laboratory-conﬁrmed inﬂuenza-related
asthma exacerbations. This review found one RCT in chil-
dren and none in adults. They were therefore unable to
conclude that inﬂuenza vaccination protected people with
asthma from asthma exacerbations related to inﬂuenza
infection.34 Our planned approach builds on the review by
Cates et al, by also including TND studies (as well as RCTs)
with laboratory-conﬁrmed inﬂuenza outcomes, and other
observational study designs with non-speciﬁc clinical out-
comes (inﬂuenza-like illness, or any other respiratory or
cardiovascular and cerebrovascular illness).
OBJECTIVES
We seek to evaluate the effectiveness of inﬂuenza vaccin-
ation in preventing inﬂuenza infection, and
inﬂuenza-related complications in people with asthma.
METHODS
Design
We will conduct a systematic review of published and
unpublished research reports.
Eligibility criteria
Types of studies
The following experimental and observational study
designs will be eligible for inclusion:
▸ RCTs or controlled clinical trials
▸ TND studies and cohort (prospective and retrospect-
ive), case-control studies and nested case-control
studies.
Systematic reviews and meta-analyses will be used only
for identifying additional studies; these will not be
included in this review.
Types of participants
According to international and national health organisa-
tions, children and adults with chronic underlying
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conditions are at high risk of developing severe
inﬂuenza-related complications.9 11 Thus, annual inﬂu-
enza vaccination is recommended in people with
asthma.
We will include papers which have adopted deﬁnitions
reﬂecting the heterogeneous deﬁnition of asthma.10
These will include people with a history of asthma symp-
toms and evidence of reversible obstruction of respira-
tory airways (eg, bronchodilator reversibility tests or
other tests) in the preceding 12 months, conﬁrmed by a
physician. Patients with asthma will be included in the
review regardless of their current prescribed treatment
for asthma.
People with a diagnosis of asthma will be included in
the review. Additionally, if participants in a study have
asthma or some other chronic medical conditions (eg,
chronic respiratory disease, chronic heart disease,
chronic liver disease, chronic kidney disease, chronic
neurological disease, diabetes, immunosuppression,
asplenia, or dysfunction of spleen), they will still be
included in the review, provided that separate data on
asthma are available from the study, or through personal
communication with the authors.
Types of intervention
Studies including any of the licensed seasonal inﬂuenza
vaccines. Studies that assess the effectiveness of pan-
demic inﬂuenza vaccine will be excluded. We will
include inﬂuenza vaccines of any type, any dose, and
any schedule, when compared with placebo, no vaccine
or other vaccine:
▸ Inactivated or live attenuated inﬂuenza vaccines
▸ Recombinant inﬂuenza vaccines
▸ Virosomal vaccines
▸ Whole, subunit, or split vaccines
▸ Monovalent, bivalent, trivalent, quadrivalent or
polyvalent.
Types of outcome measures
Inﬂuenza and asthma-related outcomes will be included
in this review. In addition, the long-term beneﬁts of the
inﬂuenza virus vaccine (during the inﬂuenza season)
and the short-term harms (2 weeks following vaccin-
ation) will be reported. The following outcomes are
listed as primary and secondary under all the above
categories:
Primary outcomes
1. Individuals with inﬂuenza-like illness symptoms, and
a laboratory-conﬁrmed diagnosis of inﬂuenza; that is,
the incidence or prevalence of laboratory-conﬁrmed
inﬂuenza infection using any of the available diagnos-
tic tests (RT-PCR or other laboratory tests);9 35
2. Asthma exacerbations
Secondary outcomes
1. Hospitalisation (asthma-related and all-cause)
2. Death (all-cause and respiratory illness)
3. Primary care consultation (asthma-related and acute
respiratory illness, including inﬂuenza-like illness)
4. Respiratory illness (clinically diagnosed or by
self-report)
5. Adverse events (asthma exacerbation and other local
or systematic reactions).9 36 37
Search methods
We will search the published literature from January
1970 to January 2016 for work investigating the effective-
ness of inﬂuenza vaccination in people with asthma.
This start date has been chosen because the earliest
study by Bell et al38 in 1978, regarding the vaccination of
children with asthma with a killed inﬂuenza virus, was
included in two previous reviews that were conducted in
1995 and 2000, respectively.39 40 There will be no lan-
guage limitation.
We will search the following biomedical databases:
MEDLINE (Ovid) (see online supplementary appendix 1),
EMBASE (Ovid), Cumulative Index to Nursing and
Allied Health Literature (CINAHL), Cochrane Central
Register of Controlled Trials (CENTRAL), Scopus,
Cochrane Database of Systematic Reviews (CDSR), Web
of Science Core Collection, ScienceDirect, WHO Library
Information System (WHOLIS), Global Health Library
and Chinese databases (CNKI, Wanfang and ChongQing
VIP). Electronic searches will be complemented by
manually searching all reference lists of published and
unpublished studies and reviews for additional studies. In
addition, forward citation search will be performed on all
identiﬁed studies using Web of Science. Furthermore,
unpublished or ongoing clinical trials will be searched in
clinical trials registry databases using http://www.
controlled-trials.com/, http://www.clinicalTrials.gov/
and the WHO International Clinical Trials Registry
Platform (ICTRP) using http://www.who.int/ictrp/en/.
We will contact pharmaceutical companies that manu-
facture inﬂuenza vaccines used in the trials to identify
other published or unpublished studies. Authors of the
studies included in the review will be contacted in case
additional information is needed. Speciﬁc search strat-
egies will be developed for each database. Two reviewers
will independently undertake searches. Any disagree-
ments that arise between the two reviewers will be
resolved by discussions, or by the involvement of a third
reviewer, if needed.
Risk of bias assessment
Two reviewers will independently assess the risk of bias
of each study. Any disagreements arising between the
two reviewers will be resolved through discussion, and if
there is still disagreement or doubt, by the involvement
of a third independent reviewer.
Randomised controlled studies
The risk of bias of experimental studies will be assessed
using the criteria outlined in the Cochrane
Collaboration’s tool for assessing risk of bias.41 Studies
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will be evaluated according to the following six domains
(1) sequence generation; (2) allocation concealment;
(3) blinding of participants and personnel, and
outcome assessors; (4) outcome ascertainment; (5)
selective outcome reporting; and (6) other bias. Risk of
bias in included studies will be divided into three cat-
egories: high, low, or unclear.
Observational and non-randomised controlled studies
The Quality Assessment Tool for Quantitative Studies
Dictionary developed by the Effective Public Health
Practice Project (EPHPP) will be used for the evaluation
of observational studies and non-randomised controlled
studies.42 The EPHPP tool contains the following eight
components: selection bias (external validity), study
design (allocation bias), confounders, blinding (detec-
tion bias), data collection methods, withdrawals and
dropouts (attrition bias), intervention integrity and ana-
lyses. The ﬁrst six components are rated as strong, mod-
erate, or weak. There is no rating for the last two
components. The overall study rating will be judged as
strong, moderate, or weak, based on the component
ratings.
Data extraction and management
The data from the observational and experimental
studies that are eligible for inclusion after having the full
text reviewed, will be extracted by two reviewers, inde-
pendently, using a data abstraction form designed for
this review. Any disagreement on the extraction of data
of the included studies will be resolved through discus-
sion or by the involvement of a third reviewer. The data
extraction form will include general information for
each study, population characteristics, intervention, out-
comes, analysis and extra useful information.
Data analysis
Separate meta-analyses will be performed for clinically
and methodologically comparable experimental and
observational studies, respectively, to estimate the inci-
dence or frequency of inﬂuenza infection and other
inﬂuenza-related complications. Fixed-effects, or
random-effects models, will be used to summarise the
ﬁndings depending on the degree of clinical heterogen-
eity of the studies.
For dichotomous outcomes, the treatment effect will
be estimated using risk ratio (RR) with 95% CIs or OR
with 95% CIs. In addition, we will report absolute mea-
sures (eg, ARR, NNV, NNH) where they have been used.
Crossover and parallel trials will be included in this
review. We will include crossover studies that assess short-
term safety in the relevant short-term safety
meta-analysis. These will be analysed appropriately,
taking the design into account.
Statistical heterogeneity will be assessed using the
standard χ2 test and the I2 statistic, which describes that
the proportion of dispersion across studies is due to true
heterogeneity rather than to a sampling error (where no
heterogeneity is represented by 0% and the highest level
of heterogeneity is 100%). Signiﬁcant (50%) statistical
heterogeneity will be investigated by conducting relevant
subgroup and sensitivity analyses (see below).41
In the case where a study is eligible to be included in
the review, but has missing data, authors will be con-
tacted for provision of further data.
All statistical analyses will be undertaken using R.
Subgroup analyses
Possible sources of heterogeneity in this review will be
investigated with the following potential comparisons, if
enough data are available from the included studies in
this review:
1. Type of inﬂuenza vaccine: Trivalent Inactivated
Vaccine (TIV) against Live Attenuated Inﬂuenza
Vaccine (LAIV);43
2. Age of participants: People vaccinated for seasonal
inﬂuenza aged 65 years or older against those less
than 65 years old;44
3. Severity of asthma: people with mild to moderate
asthma, compared with those with severe asthma;45 46
4. Immunity status: individuals with previous inﬂuenza
vaccination against those with no previous inﬂuenza
vaccination;12
5. Inﬂuenza-season mismatch: inﬂuenza seasons with
antigenic match compared with seasons with
mismatch;12
6. Inﬂuenza season—predominant strain: inﬂuenza
season with dominant strains A/H1N1, A/H3N2 and
B;12
7. Time elapsed between vaccination and inﬂuenza
infection: people developed inﬂuenza (diagnostically
conﬁrmed) in less than 14 days after being vaccinated
against those with inﬂuenza after 14 days of their vac-
cination performed.12
Sensitivity analyses
If the number of studies and data available allow, sensi-
tivity analysis will be undertaken with regards to study
quality. The analysis will be restricted to low risk of bias
trials, with adequate allocation generation, allocation
concealment and blinding. For example, unblinded
trials will not be included in the analysis. In addition,
observational studies at low risk of bias according to the
EPHPP quality assessment tool will be included in the
analysis.
In addition, we will investigate the effect of comorbid-
ities in people with asthma as a sensitivity analysis
(where they have been reported).
Publication bias
Publication bias will be explored by performing funnel
plots (where sufﬁcient data are available).
Grading the quality of evidence
The quality of the body of evidence for each outcome
will be assessed using the Grading of Recommendations
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Assessment, Development and Evaluation (GRADE)
working group methodology.47 The evaluation is based
on the following ﬁve domains: risk of bias, consistency,
directness, precision, and publication bias. There are
four levels of quality: high, moderate, low, and very low.
The GRADE summary of ﬁndings tables will be devel-
oped, and we will present the quality of all primary and
secondary outcomes.
ETHICS AND DISSEMINATION
Formal ethical approval is not required, as primary data
will not be collected. The ﬁndings will be disseminated
in peer-reviewed journals and conference presentations.
CONCLUSION
This systematic review will provide evidence regarding
the effectiveness of inﬂuenza vaccination in people with
asthma. The evidence will be obtained by searching, crit-
ically appraising, and synthesising the evidence from
experimental and observational studies of published and
unpublished literature.
Registration and publishing statement
The systematic review protocol will be registered with the
PROSPERO International Prospective Register of
Systematic Reviews (http://www.crd.york.ac.uk/prospero),
and reported using Preferred Reporting Items for
Systematic Reviews and Meta-analysis checklist to guide the
reporting of the review. The systematic review will be
shared with others.48
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